CapsoVision Announces Closing of Initial Public Offering
CapsoVision (NASDAQ: CV), a medical technology company specializing in capsule endoscopy solutions with advanced imaging and AI technologies, has successfully completed its Initial Public Offering (IPO). The company offered 5.5 million shares at $5.00 per share, raising gross proceeds of $27.5 million.
Trading commenced on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The underwriters, The Benchmark Company and Roth Capital Partners, have a 30-day option to purchase up to 825,000 additional shares at the IPO price, less underwriting discounts and commissions.
CapsoVision (NASDAQ: CV), un'azienda di tecnologia medica specializzata in soluzioni di endoscopia con capsula dotate di tecnologie avanzate di imaging e intelligenza artificiale, ha completato con successo la sua Offerta Pubblica Iniziale (IPO). La societ脿 ha offerto 5,5 milioni di azioni a 5,00 dollari per azione, raccogliendo un ricavo lordo di 27,5 milioni di dollari.
Le negoziazioni sono iniziate sul Nasdaq Capital Market il 2 luglio 2025, con il simbolo di borsa "CV". Gli underwriter, The Benchmark Company e Roth Capital Partners, hanno un'opzione di 30 giorni per acquistare fino a 825.000 azioni aggiuntive al prezzo IPO, al netto degli sconti e delle commissioni di sottoscrizione.
CapsoVision (NASDAQ: CV), una empresa de tecnolog铆a m茅dica especializada en soluciones de endoscopia por c谩psula con tecnolog铆as avanzadas de imagen e inteligencia artificial, ha completado con 茅xito su Oferta P煤blica Inicial (OPI). La compa帽铆a ofreci贸 5,5 millones de acciones a 5,00 d贸lares por acci贸n, recaudando ingresos brutos por 27,5 millones de d贸lares.
Las operaciones comenzaron en el Nasdaq Capital Market el 2 de julio de 2025, bajo el s铆mbolo burs谩til "CV". Los suscriptores, The Benchmark Company y Roth Capital Partners, tienen una opci贸n de 30 d铆as para comprar hasta 825,000 acciones adicionales al precio de la OPI, menos descuentos y comisiones de suscripci贸n.
CapsoVision (NASDAQ: CV)鞚� 觳嫧 鞓侅儊 氚� 鞚戈车歆�電� 旮办垹鞚� 頇滌毄頃� 旌§姁 雮挫嫓瓴� 靻旊（靺橃潉 鞝勲鞙茧 頃橂姅 鞚橂旮办垹 須岇偓搿�, 靹标车鞝侅溂搿� 旮办梾瓿店皽(滨笔翱)毳� 鞕勲頄堨姷雼堧嫟. 須岇偓電� 550毵� 欤�毳� 欤茧嫻 5.00雼煬鞐� 鞝滉车頃橃棳 齑� 2750毵� 雼煬鞚� 齑濎垬鞚奠潉 頇曤炒頄堨姷雼堧嫟.
瓯半灅电� 2025雲� 7鞗� 2鞚� 雮橃姢雼� 旌愴敿韯� 毵堨紦鞐愳劀 "CV"霛茧姅 韹办护 鞁臣搿� 鞁滌瀾霅橃棃鞀惦媹雼�. 鞚胳垬欤缄磤靷澑 The Benchmark Company鞕� Roth Capital Partners電� IPO 臧�瓴╈棎靹� 鞚胳垬 靾橃垬耄� 氚� 頃犾澑鞎§潉 牒� 臧�瓴╈溂搿� 斓滊寑 82毵� 5,000欤�毳� 於旉皜搿� 甑Г頃� 靾� 鞛堧姅 30鞚� 鞓奠厴鞚� 氤挫湢頃橁碃 鞛堨姷雼堧嫟.
CapsoVision (NASDAQ : CV), une entreprise de technologie m茅dicale sp茅cialis茅e dans les solutions d'endoscopie par capsule avec des technologies avanc茅es d'imagerie et d'intelligence artificielle, a r茅ussi son offre publique initiale (IPO). La soci茅t茅 a propos茅 5,5 millions d'actions au prix de 5,00 dollars par action, levant ainsi un produit brut de 27,5 millions de dollars.
La cotation a d茅but茅 sur le Nasdaq Capital Market le 2 juillet 2025, sous le symbole boursier 芦 CV 禄. Les souscripteurs, The Benchmark Company et Roth Capital Partners, disposent d'une option de 30 jours pour acheter jusqu'脿 825 000 actions suppl茅mentaires au prix de l'IPO, moins les remises et commissions de souscription.
CapsoVision (NASDAQ: CV), ein Medizintechnologieunternehmen, das sich auf Kapselendoskopiel枚sungen mit fortschrittlicher Bildgebung und KI-Technologien spezialisiert hat, hat erfolgreich seinen B枚rsengang (IPO) abgeschlossen. Das Unternehmen bot 5,5 Millionen Aktien zu je 5,00 US-Dollar an und erzielte damit Bruttoerl枚se von 27,5 Millionen US-Dollar.
Der Handel begann am 2. Juli 2025 am Nasdaq Capital Market unter dem B枚rsensymbol 鈥濩V鈥�. Die Konsortialf眉hrer, The Benchmark Company und Roth Capital Partners, haben eine 30-t盲gige Option, bis zu 825.000 zus盲tzliche Aktien zum IPO-Preis abz眉glich Underwriting-Rabatten und Provisionen zu erwerben.
- Successfully raised $27.5 million in gross proceeds through IPO
- Achieved listing on Nasdaq Capital Market
- Underwriters have option to purchase additional 825,000 shares
- Company operates in growing medical technology sector with AI capabilities
- Relatively small IPO size at $27.5 million may limit growth potential
- Trading at the lower end of typical medical technology valuations at $5.00 per share
Insights
CapsoVision raises $27.5M in IPO at $5/share, providing capital for its medical imaging and AI capsule endoscopy business.
CapsoVision has successfully completed its initial public offering, raising
The
The joint book-running managers for this offering were The Benchmark Company and Roth Capital Partners. At the
Medical technology IPOs often face significant commercialization challenges, particularly for companies competing against established players in specialized fields like endoscopy. CapsoVision's success will likely depend on market adoption rates of its capsule endoscopy technology, reimbursement pathways, and the demonstrated clinical utility of its AI-enhanced imaging capabilities in real-world settings.
SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (鈥淎I鈥�) technologies that are deployed in its capsule endoscopy solutions, today announced the closing of its initial public offering of 5,500,000 shares of common stock at a public offering price of
CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, were
The Benchmark Company, LLC and Roth Capital Partners acted as joint book-running managers for the offering.
A registration statement on Form S-1 relating to the shares was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025. The offering was made only by means of a prospectus forming a part of such registration statement. Copies of the final prospectus may be obtained from The Benchmark Company, LLC, 150 East 58th Street, 17th Floor, New York, NY 10155, Attention: Prospectus Department, or by email at [email protected]
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus庐, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company鈥檚 next pipeline product, CapsoCam Colon, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit .
Forward-Looking Statements
This press release contains or may contain forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as 鈥渆xpected鈥�, 鈥渁nticipates鈥�, 鈥渋ntends鈥�, 鈥減lans鈥�, 鈥渂elieves鈥�, 鈥減otential鈥�, 鈥渨ill鈥�, 鈥渟hould鈥�, 鈥渃ould鈥�, 鈥渨ould鈥� or 鈥渕ay鈥� and other words of similar meaning. These forward-looking statements are based on the Company鈥檚 current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions, and other risks described in the Company鈥檚 registration statement on Form S-1 filed with the SEC. Forward-looking statements speak only as of the date of this press release, and CapsoVision undertakes no obligation to update or revise these statements, except as required by law.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Kevin Lundquist
Chief Financial Officer, CapsoVision, Inc.
[email protected]
Media Contact
Leslie Strickler and Paul Spicer
脢tre Communications
聽| (804) 240-0807
聽| (804) 503-9231
FAQ
How much did CapsoVision (CV) raise in its IPO?
When did CapsoVision (CV) stock begin trading on Nasdaq?
What is CapsoVision's (CV) main business focus?
Who were the underwriters for CapsoVision's (CV) IPO?
What is the additional share purchase option in CapsoVision's (CV) IPO?
